Recipharm completes Blow-fill-seal expansion at Kaysersberg facility
Recipharm, the contract development and manufacturing organisation (CDMO), announces its new Blow-fill-seal machinery is now operational following a substantial investment last year at its facility in Kaysersberg, France.
The EUR 18 million investment adds a new Blow-fill-seal high-speed filling and packaging line to the site, taking the total number of lines to eight and increasing the facility’s manufacturing capacity by 200 million unidoses/year.
In addition, the investment adds 2,400 square metres to the facility creating space for a further three machines, which will ultimately allow the site to manufacture over 1.2 billion unidoses/year.
Yves Buelens, General Manager at Recipharm’s Kaysersberg site, said: “This latest investment is in direct response to customer demand for single-dose and sterile manufacturing services, such as aseptic processing for eye care and ear care products, particularly from markets such as the US, Turkey, Australia and Canada. This project was supported by the Region Grand Est and the CCI Alsace Eurométropole as part of employment-related actions”.
“Recipharm has only owned the facility for two years and during that time have taken some very fast and positive decisions to invest in Kaysersberg. We have worked hard to develop a flexible service that can cater for even the most complex of projects. Adding the line to our facility will allow us to take on new customer projects more quickly, as well as continue to meet our current customers’ requirements. The additional space we’ve added also means we are also well positioned for further growth in line with future customer demand.”
The Kaysersberg site, located in Alsace, France, is a facility specialising in Blow-fill-seal technology for sterile liquids. The site manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications.
För mediaförfrågningar kontakta Lindsay Baldry på ramarketing: firstname.lastname@example.org, +44 191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.